Two Alzheimer's Candidate Vaccines

( were able to complete the study without any problems )

PleaseHelpSupport Alzheimer's Research Today!
Your Alzheimer's donation will help billionslive without it. Donate online now

AFFiRiS AG today announced that the primary endpoints have been met for the Phase I clinical studies of its two Alzheimer's vaccines AD01 and AD02, which demonstrated favourable safety and tolerability profiles. These results trigger a 10 million EUR milestone payment from licensee GlaxoSmithKline Biologicals. All 48 patients treated in these studies were given four vaccinations which were well tolerated and no serious side effects associated with the vaccine candidates were observed.

The results demonstrate the potential value of the AFFITOME® technology, which forms the platform for both of these vaccines and could result in a generation of highly specific vaccines. While analysing the clinical outcome in detail the company, together with GSK Biologicals is progressing to the next development stage. AFFiRiS AG is also using AFFITOME® technology to develop vaccines for Parkinson's disease, atherosclerosis and four other indications.

Commenting on the results, AFFiRiS' CEO, Dr. Walter Schmidt, said: "This initial demonstration of safety and tolerability is an outstanding milestone in our joint efforts with GSK Biologicals to develop a therapeutic Alzheimer's vaccination. However, the results also highlight the potential capability of our AFFITOME® technology, which forms the basis for the two vaccine candidates. This technology is also the platform for our six other vaccine programmes, including Parkinson's and atherosclerosis currently under development. The results not only represent an important milestone in the development of our Alzheimer’s vaccination but also confirm our basic strategy. We will be investing all of this milestone payment in our research and development projects."

In October 2008 AFFiRiS concluded a licensing agreement with GSK Biologicals on jointly developing the Alzheimer's vaccines AD01 and AD02. Comprising total payments of up to EUR 430 million upon successful commercialisation, and the progress that has now been achieved is a key milestone in the collaboration. As part of this agreement, GSK Biologicals has gained access to the AFFITOME® technology of AFFiRiS, in the field of Alzheimer vaccination.

In other indications AFFiRiS retains the exclusive rights to this technology. In summary, the AFFITOME® technology delivers short synthetic peptides that mimic functionally highly specific original structures such as those of antigens. This can be used to generate vaccines - particularly important with Alzheimer's vaccines - that lead to the formation of antibodies which target only detrimental derivatives of human proteins and leaving their healthy precursor forms alone.

The clinical studies to test the two therapeutic Alzheimer's vaccines were conducted in Vienna, Austria, using two different peptide antigens. 24 patients with mild to moderate stage of the disease were recruited for each of the two studies. Each patient received four vaccinations at four-weekly intervals. Both groups were divided into two subgroups of 12 patients who received the vaccine with or without an adjuvant. Commenting on the results, Dr. Frank Mattner, CSO of AFFiRiS AG, said: "All 48 patients were able to complete the study without any problems, with the data now evaluated demonstrating acceptable tolerability of vaccine candidates AD01 and AD02. None of the 48 participants in the studies showed any indications of meningoencephalitis or other autoimmune reactions that have caused severe problems for other Alzheimer's vaccine candidates. We are now analysing the immunological data and results of the cognitive tests in detail." ...http://www.scienceblog.com

You're as old as you eat

Keeping in peak condition in old age can be boosted by nutrition, which scientists are proving is a powerful weapon in fighting off diseases. As new research shows that olive oil could play a vital role in protecting against dementia, we look at the key foods that have shown to be an ally against ageing. ...http://www.dailymail.co.uk/health/article-1221070/Youre-old-eat--Our-guide-foods-fight-age.html?ITO=1490

Беларусь ТВ

Posted YVN